척수성 근위축증(SMA) 치료 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The global spinal muscular atrophy (SMA) treatment market size is expected to reach USD 27.18 Billion in 2034 from USD 5.86 Billion in 2025, growing at a CAGR of 18.58% during 2026-2034.The spinal muscular atrophy (SMA) treatment market has grown rapidly due to breakthroughs in genetic therapies and early diagnosis initiatives. Previously considered a fatal pediatric disorder with limited options, SMA now benefits from disease-modifying drugs and gene replacement therapies. Increased newborn screening and earlier intervention have significantly improved patient outcomes, driving market expansion.

Key drivers include advancements in antisense oligonucleotide therapies, gene therapy innovations, and strong regulatory incentives for rare diseases. Strategic collaborations between biotech firms and healthcare providers have enhanced distribution and patient access. High awareness among clinicians and patient advocacy groups has further supported early diagnosis and timely treatment initiation.

Looking ahead, the market is expected to evolve with next-generation gene-editing approaches and improved delivery systems. Long-term efficacy data and expanded indications may broaden patient eligibility. Nevertheless, high therapy costs and reimbursement challenges remain significant considerations. Continued innovation and supportive healthcare policies will shape future growth trajectories.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Type

• Type 1
• Type 2
• Type 3
• Type 4

By Treatment

• Gene Therapy
• Drug

By Route of Administration

• Oral
• Injection

COMPANIES PROFILED

• Biogen, Roche, Novartis, Scholar Rock, Ionis Pharmaceuticals, PTC Therapeutics, Astellas Pharma, Solid Biosciences, Regeneron, Cytokinetics, Sarepta Therapeutics, BioMarin, AveXis/Novartis, Genentech/Roche, Ionis/Biogen, Dynacure, FibroGen, Capricor Therapeutics, Sarepta, Scholar Rock

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET: BY TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Type
• 4.2. Type 1 Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Type 2 Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Type 3 Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Type 4 Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET: BY TREATMENT 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Treatment
• 5.2. Gene Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Drug Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Route Of Administration
• 6.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Injection Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET: BY REGION 2022-2034 (USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Type
  • 7.2.2 By Treatment
  • 7.2.3 By Route Of Administration
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Type
  • 7.3.2 By Treatment
  • 7.3.3 By Route Of Administration
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Spain
  • 7.3.9 Russia
  • 7.3.10 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Type
  • 7.4.2 By Treatment
  • 7.4.3 By Route Of Administration
  • 7.4.4 China
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 India
  • 7.4.8 Australia
  • 7.4.9 South East Asia
  • 7.4.10 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Type
  • 7.5.2 By Treatment
  • 7.5.3 By Route Of Administration
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Type
  • 7.6.2 By Treatment
  • 7.6.3 By Route Of Administration
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL SPINAL MUSCULAR ATROPHY (SMA) TREATMENT INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Biogen
  • 9.2.2 Roche
  • 9.2.3 Novartis
  • 9.2.4 Scholar Rock
  • 9.2.5 Ionis Pharmaceuticals
  • 9.2.6 PTC Therapeutics
  • 9.2.7 Astellas Pharma
  • 9.2.8 Solid Biosciences
  • 9.2.9 Regeneron
  • 9.2.10 Cytokinetics
  • 9.2.11 Sarepta Therapeutics
  • 9.2.12 BioMarin
  • 9.2.13 AveXis/Novartis
  • 9.2.14 Genentech/Roche
  • 9.2.15 Ionis/Biogen
  • 9.2.16 Dynacure
  • 9.2.17 FibroGen
  • 9.2.18 Capricor Therapeutics
  • 9.2.19 Sarepta
  • 9.2.20 Scholar Rock